2024-04-30 08:01 | UU:VXRT | | News Release200 | Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers |
2024-03-27 08:00 | UU:VXRT | | News Release200 | Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 |
2024-03-20 08:00 | UU:VXRT | | News Release200 | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2024-03-14 16:01 | UU:VXRT | | News Release200 | Vaxart Provides Business Update and Reports Full Year 2023 Financial Results |
2024-03-07 08:00 | UU:VXRT | | News Release200 | Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 |
2024-03-06 08:00 | UU:VXRT | | News Release200 | Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director |
2024-02-05 08:00 | UU:VXRT | | News Release200 | Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge |
2024-01-19 08:30 | UU:VXRT | | News Release200 | Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate |
2024-01-16 09:25 | UU:VXRT | | News Release200 | Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management |
2024-01-16 09:23 | UU:VXRT | | News Release200 | Vaxart, Inc. Announces Management Change |
2023-12-21 08:00 | UU:VXRT | | News Release200 | Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers |
2023-11-02 16:01 | UU:VXRT | | News Release200 | Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results |
2023-11-02 08:00 | UU:VXRT | | News Release200 | Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers |
2023-10-26 08:00 | UU:VXRT | | News Release200 | Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2 |
2023-10-11 08:00 | UU:VXRT | | News Release200 | Vaxart to Present at World Vaccine Congress Europe 2023 ‚ on October 18-19 |
2023-09-21 08:00 | UU:VXRT | | News Release200 | Vaxart ‚ to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference |
2023-09-06 16:05 | UU:VXRT | | News Release200 | Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate |
2023-08-03 16:01 | UU:VXRT | | News Release200 | Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results |
2023-07-27 08:00 | UU:VXRT | | News Release200 | Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3 |
2023-07-06 08:00 | UU:VXRT | | News Release200 | Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate |
2023-06-26 16:45 | UU:VXRT | | News Release200 | Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement |
2023-06-21 16:30 | UU:VXRT | | News Release200 | Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET |
2023-06-07 09:16 | UU:VXRT | | News Release200 | Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock |
2023-06-06 16:01 | UU:VXRT | | News Release200 | Vaxart, Inc. Announces Proposed Public Offering of Common Stock |
2023-06-06 08:00 | UU:VXRT | | News Release200 | Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate |
2023-05-31 08:00 | UU:VXRT | | News Release200 | Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET |